Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$164,134 Mln
Revenue (TTM)
$297,195 Mln
Net Profit (TTM)
$98,500 Mln
ROE
0.6 %
ROCE
34.5 %
P/E Ratio
10.4
P/B Ratio
5.4
Industry P/E
--
EV/EBITDA
7.4
Div. Yield
4.9 %
Debt to Equity
0.7
Book Value
$43.6
EPS
$22.1
Face value
--
Shares outstanding
3,363,575,209
CFO
$545,605.00 Mln
EBITDA
$626,068.00 Mln
Net Profit
$444,078.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S - ADR
| -27.3 | -1.3 | -27.3 | -45.6 | -22.5 | 1.8 | 3.0 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S - ADR
| -40.9 | -16.7 | 52.9 | 20.8 | 63.5 | 23.3 | 28.7 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S - ADR
|
37.0 | 164,133.8 | 297,195.2 | 98,500.3 | 46.4 | 58.4 | 10.4 | 5.4 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 105.4 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,120.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.2 | 2.8 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 6,767.7 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.1 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,320.2 | 158.3 | -68.9 | -29.3 | -113 | -- | 74.1 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and... Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Read more
President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Headquarters
Bagsvaerd
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Novo Nordisk A/S - ADR is $36.98 (NYSE) as of 02-Apr-2026 19:59 EDT. Novo Nordisk A/S - ADR has given a return of -22.54% in the last 3 years.
The P/E ratio of Novo Nordisk A/S - ADR is 10.39 times as on 02-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
2.30
|
1.17
|
|
2024
|
3.80
|
2.67
|
|
2023
|
5.54
|
4.35
|
|
2022
|
11.02
|
7.33
|
|
2021
|
10.76
|
7.26
|
The 52-week high and low of Novo Nordisk A/S - ADR are Rs 81.44 and Rs 35.13 as of 05-Apr-2026.
Novo Nordisk A/S - ADR has a market capitalisation of $ 164,134 Mln as on 02-Apr-2026. As per SEBI classification, it is a company.
Before investing in Novo Nordisk A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.